Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 14/20 | 0.74 |
| ▸ | KIT | P10721 | 4/20 | 0.74 |
| ▸ | FLT3 | P36888 | 4/20 | 0.74 |
| ▸ | AURKA | O14965 | 2/20 | 0.74 |
| ▸ | EGFR | P00533 | 1/20 | 0.74 |
| ▸ | RET | P07949 | 1/20 | 0.74 |
| ▸ | MET | P08581 | 1/20 | 0.74 |
| ▸ | SRC | P12931 | 1/20 | 0.74 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.74 |
| ▸ | KDR | P35968 | 1/20 | 0.74 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.74 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.74 |
| ▸ | MERTK | Q12866 | 1/20 | 0.74 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.74 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.74 |
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30090843 | 1.00 | AXL (0.74) | AXLKITFLT3AURKAEGFR | |
| SCHEMBL20351831 | 0.93 | AXL (0.79) | AXLKITFLT3AURKAEGFR | |
| SCHEMBL1887473 | 0.90 | AXL (0.68) | AXLKITFLT3AURKAEGFR | |
| SCHEMBL30090868 | 0.88 | AXL (0.81) | AXLKITFLT3AURKAEGFR | |
| SCHEMBL2056553 | 0.88 | AXL (0.81) | AXLKITFLT3AURKAEGFR | |
| SCHEMBL24820931 | 0.88 | AXL (0.73) | AXLKITFLT3AURKAEGFR | |
| SCHEMBL30121452 | 0.88 | AXL (0.81) | AXLKITFLT3AURKAEGFR | |
| SCHEMBL467836 | 0.88 | AXL (0.81) | AXLKITFLT3AURKAEGFR | |
| SCHEMBL1891760 | 0.88 | AXL (0.59) | AXLKITFLT3AURKAEGFR | |
| SCHEMBL1639408 | 0.88 | AXL (0.80) | AXLKITFLT3AURKAEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709482-B2 | angiogenesis and/or cell proliferation, carcinoma, myeloid leukemia, endometriosis; inhibitors of the receptor protein tyrosine kinase; N3-(3-cyclopentyl-1,2,3,4,5,6-hexahydrobenzo[d]azocin-8-yl)-1-(6-fluoroquinazolin-4-yl)-1H-1,2,4-triazole-3,5-diamine | RIGEL PHARMACEUTICALS, INC. (US) | 2010-05-04 | — | — | US | claimed |
| US-20080188455-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2008-08-07 | — | — | US | claimed |
| US-20230372337-A1 | Combination Therapy Comprising an AXL Inhibitor | BERGENBIO ASA (NO) | 2023-11-23 | — | — | US | disclosed |
| US-20230250169-A1 | AXL Inhibitors for Antiviral Therapy | BERGENBIO ASA (NO) | 2023-08-10 | — | — | US | disclosed |
| US-20230151100-A1 | Method of Selecting Patients for Treatment with a Combination of an AXL Inhibitor and an Immune Checkpoint Modulator | BERGENBIO ASA (NO) | 2023-05-18 | — | — | US | disclosed |
| US-20230149397-A1 | Combination Therapy with AXL Inhibitor and Immune Checkpoint Modulator or Oncolytic Virus | BERGENBIO ASA (NO) | 2023-05-18 | — | — | US | disclosed |
| WO-2022268026-A1 | 1,2,4-TRIAZOLE COMPOUNDS AS AXL INHIBITORS | 南京正大天晴制药有限公司 | 2022-12-29 | — | — | WO | disclosed |
| US-11534440-B2 | Combination therapy with Axl inhibitor and immune checkpoint modulator or oncolytic virus | BERGENBIO ASA (NO) | 2022-12-27 | — | — | US | disclosed |
| US-20210379064-A1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | MIDCAP FINANCIAL TRUST | 2021-12-09 | — | — | US | disclosed |
| EP-3804723-A1 | COMBINATION THERAPY | BerGenBio ASA (NO) | 2021-04-14 | — | — | EP | disclosed |
| WO-2021032883-A1 | COMBINATION THERAPY OF A PATIENT SUBGROUP | BERGENBIO ASA (NO) | 2021-02-25 | — | — | WO | disclosed |
| US-20130338161-A1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | RIGEL PHARMACEUTICALS INC (US) | 2013-12-19 | — | — | US | disclosed |
| US-8546433-B2 | Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer | RIGEL PHARMACEUTICALS, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120264740-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-8168636-B2 | Polycyclic heteroaryl substituted triazoles useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20110098274-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| US-20100196511-A1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | RIGEL PHARMACEUTICALS, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| US-20100168416-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-01 | — | — | US | disclosed |
| US-7709482-B2 | angiogenesis and/or cell proliferation, carcinoma, myeloid leukemia, endometriosis; inhibitors of the receptor protein tyrosine kinase; N3-(3-cyclopentyl-1,2,3,4,5,6-hexahydrobenzo[d]azocin-8-yl)-1-(6-fluoroquinazolin-4-yl)-1H-1,2,4-triazole-3,5-diamine | RIGEL PHARMACEUTICALS, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| US-20080188455-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100196511-A1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | AXL, FLT3, MET | AXL 1/4885KIT 444/4885FLT3 2/4885 |
| US-20230149397-A1 | Combination Therapy with AXL Inhibitor and Immune Checkpoint Modulator or Oncolytic Virus | AXL, CD274, HAVCR2 | AXL 1/4885KIT 2149/4885FLT3 29/4885 |
| US-11534440-B2 | Combination therapy with Axl inhibitor and immune checkpoint modulator or oncolytic virus | AXL, CD274, HAVCR2 | AXL 1/4885KIT 2345/4885FLT3 33/4885 |
| US-20230372337-A1 | Combination Therapy Comprising an AXL Inhibitor | AXL, CD274, CD47 | AXL 1/4885KIT 2025/4885FLT3 28/4885 |
| US-20230250169-A1 | AXL Inhibitors for Antiviral Therapy | FLT3, AXL, SARS1 | AXL 2/4885KIT 1463/4885FLT3 1/4885 |
| US-20100168416-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | AXL, TYRO3, ERBB3 | AXL 1/4885KIT 362/4885FLT3 5/4885 |
| US-20080188455-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | AXL, TYRO3, ERBB3 | AXL 1/4885KIT 362/4885FLT3 5/4885 |
| US-20110098274-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | AXL, TYRO3, ERBB3 | AXL 1/4885KIT 362/4885FLT3 5/4885 |
| US-20120264740-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | AXL, TYRO3, ERBB3 | AXL 1/4885KIT 362/4885FLT3 5/4885 |
| US-20210379064-A1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | AXL, FLT3, MET | AXL 1/4885KIT 444/4885FLT3 2/4885 |
| US-20230151100-A1 | Method of Selecting Patients for Treatment with a Combination of an AXL Inhibitor and an Immune Checkpoint Modulator | STK11, MERTK, AXL | AXL 3/4885KIT 890/4885FLT3 33/4885 |
| US-20130338161-A1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | AXL, FLT3, MET | AXL 1/4885KIT 444/4885FLT3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.